Tech and biotechnology executives are urging immediate legislative action to regulate the synthetic biology sector. In a joint letter dated June 3, leaders from OpenAI, Anthropic, Google DeepMind, and more than fifty prominent figures in artificial intelligence, biotechnology, and national security have called on U.S. lawmakers to mandate stricter oversight of DNA synthesis firms. The coalition warns that rapid advances in artificial intelligence are systematically eroding the technical barriers that historically prevented malicious actors from accessing biological weapons. The primary concern centers on the convergence of generative AI tools and increasingly affordable laboratory equipment. Experts note that large language models and specialized bioinformatics platforms could enable individuals with minimal training to design deadly pathogens or toxins. To mitigate this risk, the signatories are demanding Congress pass legislation requiring all U.S. DNA synthesis companies and manufacturing equipment providers to implement rigorous customer vetting procedures. The proposal also mandates comprehensive record-keeping to ensure that any order evading initial screening can be accurately traced, a transparency measure the authors argue will serve as a significant deterrent against misuse. This regulatory push aligns with the Biosecurity Modernization and Innovation Act, currently under consideration by a bipartisan group in the U.S. Senate. The pending legislation would direct the Department of Commerce to establish new screening protocols within one year. Industry advocates suggest the executive coalition letter provides critical momentum to advance the bill through Congress. Historical context shows that while several DNA synthesis firms and research funders previously adopted voluntary screening agreements, advocates now argue that universal compliance is essential given the accelerating pace of technological development. Security experts emphasize that domestic regulation represents only one component of a comprehensive bioweapon mitigation strategy. Hayley Anne Severance, deputy vice president of NTI bio, noted that effective risk reduction requires coordinated international standards, particularly among nations with substantial synthesis capabilities like China. Additionally, the AI sector must proactively implement safety guardrails, such as configuring conversational models to reject requests for nonexpert laboratory protocols and restricting access to specialized protein and chemical design tools. The coalition acknowledges the inherent challenge of balancing open scientific progress with stringent biosecurity protocols. While several participating technology firms have already implemented internal safety measures, the June 3 communication does not specify whether new regulatory obligations should explicitly target AI developers. The ongoing legislative debate will ultimately determine how U.S. policy addresses the intersection of artificial intelligence and biological manufacturing, with implications for global health security and technological innovation.